ABCG2 polymorphisms and susceptibility to ARV-associated hepatotoxicity

Area of Science:

• Pharmacogenomics
• HIV Medicine
• Hepatotoxicity Research

Background:

• The ABCG2 421C/A polymorphism influences antiretroviral (ARV) drug absorption and is linked to efavirenz side effects.
• Understanding genetic variations in ABCG2 is crucial for managing ARV therapy in HIV patients.

Purpose of the Study:

• To investigate the association between ABCG2 genetic variations (34G/A and 421C/A) and the risk of developing antiretroviral therapy-induced hepatotoxicity in HIV-infected patients.
• To explore the role of these genetic variations in HIV disease progression.

Main Methods:

• Genotyping of ABCG2 34G/A (rs2231137) and 421C/A (rs2231142) using PCR-restriction fragment length polymorphism (PCR-RFLP).
• Study included 149 HIV patients (33 with hepatotoxicity) and 151 healthy controls.

Main Results:

• The ABCG2 34GA genotype and 34A allele were associated with an increased risk of developing hepatotoxicity (OR=1.58-1.50).
• The GA haplotype showed a significant association with hepatotoxicity (OR=2.37-2.49) and an elevated risk when comparing HIV patients with hepatotoxicity to controls (OR=1.73).
• The ABCG2 34GA genotype was linked to HIV disease progression (OR=1.97), and the 421AA genotype was associated with tobacco use and HIV progression (OR=11.07).

Conclusions:

• The ABCG2 GA haplotype may increase the risk and severity of hepatotoxicity.
• Individuals with the ABCG2 34A allele are at higher risk for hepatotoxicity.
• The ABCG2 34GA genotype is associated with an increased risk of progression in advanced HIV stages.